glp 1 vs gip Free Comparison Chart: GLP-1 and GIP/GLP-1 Receptor Agonists for Type 2 Diabetes 🔗 Link in bio #FOAMed #Type2Diabetes #GLP1 Indications for GLP-1/GIP RA Summary

Ascletis ASC35, a once-monthly GLP-1/GIP peptide using a self-assembling lipid depot, cleared FDA IND for Phase 1 head-to-head vs weekly tirzepatide June 23.

Compared with SGLT-2 inhibitor use, GLP-1 receptor agonist use was not associated with an increased risk of pulmonary aspiration (pooled risk ratio 0.98, 95% CI 0.73 to 1.31), although it was associated with a higher risk for discontinuation of endoscopy (1.99, 1.56 to 2.53)

Across studies, fat mass decline predominated, whereas reductions in lean body mass were modest

A 2024 RCT found semaglutide reduced hip bone density by 2.6% and lumbar spine by 2.1% in one year

Compounding pharmacies and investors have brought legal challenges to enjoin the FDA from enforcing the changes to the shortage list, but have so far been unsuccessful